Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

TOBI Podhaler 224 Capsule Monthly Pack

Known as: TOBRAMYCIN 28 mg RESPIRATORY (INHALATION) CAPSULE [TOBI Podhaler]_#1, {224 (Tobramycin 28 MG Inhalant Powder [Tobi]) } Pack [TOBI Podhaler Kit], TOBI Podhaler Kit, 4 Weekly Packs, each including 56 capsules (7 Blister Cards of 8 Capsules) 
National Institutes of Health

Related topics

Related topics

7 relations
1,2-distearoyllecithinCalcium ChloridePackSulfuric acid
Expand

Broader (2)

Tobramycin 28 MG Inhalant Powder [Tobi]{224 (Tobramycin 28 MG Inhalant Powder) } Pack

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Treatment compliance in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection treated with tobramycin inhalation powder: The FREE study.
BACKGROUND A high treatment burden with nebulised therapies in cystic fibrosis (CF) patients is the major limitation for… Expand
2017
2017
Physical Characterization of Tobramycin Inhalation Powder: II. State Diagram of an Amorphous Engineered Particle Formulation.
Tobramycin Inhalation Powder (TIP) is a spray-dried engineered particle formulation used in TOBI Podhaler, a drug-device… Expand
2016
2016
The development of a single-use, capsule-free multi-breath tobramycin dry powder inhaler for the treatment of cystic fibrosis.
The aerosol performance and delivery characteristics of tobramycin for the treatment of respiratory infection were evaluated… Expand
2015
2015
ePS03.3 Longer term tolerance and likely adherence to TOBI Podhaler in CF adults
Background In a 6-month clinical trial, TOBI Podhaler (TIP) has been shown to be safe and generally well tolerated compared to… Expand
2014
2014
Population Pharmacokinetics of Inhaled Tobramycin Powder in Cystic Fibrosis Patients
Tobramycin powder for inhalation (TOBI Podhaler or TIP) is approved for the treatment of Pseudomonas aeruginosa airway infection… Expand
Review
2013
Review
2013
Colistimethate sodium powder and tobramycin powder for inhalation for the treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis: systematic review and economic model.
BACKGROUND Cystic fibrosis (CF) is an inherited condition characterised by the abnormal transport of chloride ions across… Expand
  • table 1
  • figure 4
  • figure 5
  • table 2
  • table 8
Review
2013
Review
2013
[TOBI Podhaler for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis patients].
  • F. Piérart
  • Revue medicale de Liege
  • 2013
    • Corpus ID: 28916625
TOBI Podhaler is the first dry powder formulation of tobramycin for inhaled therapy of chronic Pseudomonas aeruginosa infection… Expand
Highly Cited
2011
Highly Cited
2011
Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial.
BACKGROUND A light-porous-particle, dry-powder formulation of tobramycin was developed, using PulmoSphere® technology, to improve… Expand
  • figure 1
  • table 2
  • table 1
  • figure 2
  • table 3
Review
2011
Review
2011
Tobramycin administered by the TOBI® Podhaler® for persons with cystic fibrosis: a review
From its introduction, the antibiotic tobramycin has been an important tool in the management of persons with cystic fibrosis (CF… Expand
  • figure 1
  • figure 2
  • table 1
2008
2008
Impacto clínico y evolución microbiológica tras tratamiento con tobramicina inhalada en bronquiectasias colonizadas por Pseudomonas aeruginosa.
espanolFUNDAMENTO: Evaluar la eficacia de tobramicina nebulizada �TOBI®� en la modificacion de la historia natural de la… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE